Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
RESEARCH TOOLSreports
VRDN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.40 - $27.20
Previous CloseN/A
Volume201.32K
Average Volume (3M)1.13M
Market Cap
$1.26B
Enterprise Value$969.97M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.97
Next Earnings
May 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.31
Shares Outstanding79,212,746
10 Day Avg. Volume1,076,910
30 Day Avg. Volume1,125,747
Standard Deviation0.24
R-Squared0.09
Alpha0.00502
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4157.36
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-962.28
Enterprise Value/Ebitda-3.84
Forecast
1Y Price Target
$41.92Price Target Upside152.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsVRDN has reported positive Phase 3 data for lead asset veligrotug from the THRIVE studies in active and chronic thyroid eye disease.
Financial HealthVRDN is well funded with a balance of cash and equivalents of $753MM at the end of Q3 providing runway into H2:27.
Market PositioningVRDN is well-positioned in the TED space with a potentially differentiated offering based on less frequent dosing for SC ‘003 compared to the competition.
Bears Say
Adverse EventsThe associated TEAE discontinuation rate with linsitinib was meaningfully higher than the rate observed with veligrotug in THRIVE.
Competitor ComparisonIt's unlikely that VRDN-001 can deliver both superior efficacy and better tolerability unless the lower drug volume leads to tolerability benefits.
Efficacy ConcernsLinsitinib's efficacy was meaningfully lower than that of Viridian's veligrotug in the pivotal THRIVE study, with a slower onset of efficacy.
---
Ownership Overview
4.38% Insiders
24.30% Mutual Funds
57.40% Other Institutional Investors
1.28% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRDN FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest stock price was $11.40 and its highest was $27.20 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Viridian Therapeutics’s market cap is $1.26B.
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 75 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Nov 12, 2024. The company reported -$1.15 earnings per share for the quarter, missing the consensus estimate of -$1.057 by -$0.093.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 79,212,746 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$1.15 in its last earnings report, missing expectations of -$1.057. Following the earnings report the stock price went down -12.758%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Currently, no hedge funds are holding shares in VRDN
---
Viridian Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.92 (152.23% Upside)
$41.92 (152.23% Upside)
Blogger Sentiment
Bullish
VRDN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 23.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.81%
12-Months-Change
Fundamentals
Return on Equity
-51.88%
Trailing 12-Months
Asset Growth
134.79%
Trailing 12-Months
Company Description
Viridian Therapeutics
Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
---
VRDN Stock 12 Month Forecast
Average Price Target
$41.92
▲(152.23% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Regeneron
―
Ultragenyx Pharmaceutical
―
Argenx Se
―
Immunovant
―
Best Analysts Covering VRDN
1 Year
1 Year Success Rate
19/38 ratings generated profit
1 Year Average Return
+1.86%
reiterated a buy rating 2 months ago
Copying Laura Chico's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +1.86% per trade.
---